Novartis’ $1.5B ADC Acquisition Highlights Growing Demand for Antibody Technologies, Benefiting VERAXA Biotech

VERAXA Biotech (NASDAQ: VRXA) operates in one of biotechnology’s most active partnering environments, with pharmaceutical companies continuing to commit billions of dollars to differentiated antibody therapeutics. The latest example came this week as Novartis agreed to acquire Myricx Bio for $1.1 billion upfront, plus up to $400 million in milestone payments, to gain access to the company’s novel N-myristoyltransferase inhibitor (“NMTi”) payload platform and two lead ADC programs. The acquisition reflects continued industry demand for innovative antibody technologies capable of addressing limitations of existing cancer therapies.

Novartis has agreed to acquire Myricx Bio for $1.1 billion upfront, with up to $400 million in milestone payments, reinforcing strong pharmaceutical demand for next-generation antibody-drug conjugate (“ADC”) technologies. The latest transaction adds to a growing list of multibillion-dollar ADC and T-cell engager (“TCE”) deals, highlighting continued strategic investment in differentiated antibody platforms.

The Novartis transaction follows a series of major antibody therapeutics deals, including Jazz Pharmaceuticals’ collaboration with AbCellera, Gilead Sciences’ acquisition of Tubulis and multiple multibillion-dollar ADC licensing agreements. VERAXA is advancing proprietary antibody therapeutics spanning both ADCs and TCEs through its patented BiTAC platform, positioning the company within two therapeutic categories that continue to attract significant pharmaceutical investment, strategic collaborations and acquisition activity.

For VERAXA shareholders, the Novartis deal validates the market potential of next-generation antibody technologies. As big pharma seeks to bolster oncology pipelines, platforms like VERAXA’s BiTAC—which enables both bispecific T-cell engagers and bispecific ADCs—become increasingly attractive targets for partnerships or acquisitions. The implications extend beyond VERAXA: the broader ADC market, projected to grow substantially, benefits from continued validation by major players like Novartis. For the industry, these deals signal a shift toward more sophisticated payloads and targeting mechanisms, driving innovation in cancer treatment.

VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company’s BiTAC(R) platform is a registered trademark of VERAXA Biotech GmbH, and the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development.

Forward-looking statements in this article involve risks and uncertainties, as detailed in the company’s filings with the SEC. For the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.